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Background
Human cells are critical raw materials for research and
manufacturing of cell therapy products. However, acces-
sibility to freshly procured cells can be limited, creating
a crucial need for a suitable alternative to fresh cells
that are viable and functional, especially when transport-
ing materials globally.
Methods
At HemaCare, we have investigated the viability and func-
tionality of lymphocytes, both fresh and cryopreserved,
from leukopaks (leukapheresis collections) procured
within our FDA registered cGMP donor collection facility.
Fresh leukopaks (LP) from healthy donors were evaluated
for cell viability via flow cytometry over the course of
seven days.
Results
Studies found that viability of LPs in autologous plasma at
room temperature were greater than 80% up to 144 hours
post collection. However, the cell counts decreased steadily
over time, leading us to look at how cryopreservation might
help to ameliorate these drawbacks in typical LP transport.
The viability of T cells, monocytes, B cells, and natural killer
(NK) cells from LP were evaluated from the same donor
pre- and post-cryopreservation. Preliminary data for whole
LPs shows that post-cryopreserved viability averages 97.5%
(+/- 1.2 SEM). The distribution of the CD3+, CD4+, and
CD8+ populations were 43.4%, 28.7%, and 12.2%, respec-
tively, within the total LP. Distribution of B-cells, NK cells,
and monocytes shows 8.38%, 12.5%, and 20.4%, respectively.
T cell functionality data was also obtained, as this cell type
is sensitive to the cryopreservation process. Results of
CFSE-labeled T cells functional assays show multiple divi-
sions over 5 days, and high expression of Ki67 and CD25
after 5 day monocyte derived DC stimulation.
Conclusions
These preliminary results suggest that cryopreserved LPs
can serve as an acceptable alternative to fresh LPs. Thus,
cryopreserved LPs are a valuable and significant option for
emerging autologous and allogeneic cell therapies which
require apheresis shipments from collection centers to cell
therapy processing facilities around the world.
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